<DOC>
	<DOCNO>NCT00295854</DOCNO>
	<brief_summary>To evaluate safety efficacy 8 week treatment MN-001 500 mg bid , 500 mg daily vs. placebo patient Interstitial Cystitis .</brief_summary>
	<brief_title>Phase II Study Efficacy Safety Two Dosing Regimens MN-001 Patients With Interstitial Cystitis</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , multi-center study evaluate efficacy safety two dose regimen MN-001 patient Interstitial Cystitis ( IC ) . Patients screen study eligibility within seven nine day randomization . Eligible patient randomize 1:1:1 ratio receive either 500 mg MN-001 bid , 500 mg MN-001 daily placebo . Patients dispense study drug begin Baseline ( Visit 2 ) return study center Visit 3 ( 28 day ± 2 day Baseline ) , Visit 4 ( 56 day ± 2 day Baseline ) , end study safety efficacy assessment . The patient contact telephone Week 6 ( 42 day ± 2 day Baseline ) interim follow . Study drug dispense Visits 2 3 . Safety assessment include adverse event , physical examination , clinical laboratory testing , change vital sign . Efficacy assessment include percentage patient least `` moderately improve '' treatment group use patient report Global Response Assessment ( GRA ) ( see Appendix 1 ) . Secondary assessment include decrease bladder pain/urgency base change patient rating baseline endpoint use GRA ( see Appendix 1 ) , modify Pelvic Pain Urgency/Frequency ( PUF ) Patient Symptom Scale ( see Appendix 2 ) O'Leary Sant IC Symptom Problem Index .</detailed_description>
	<mesh_term>Cystitis</mesh_term>
	<mesh_term>Cystitis , Interstitial</mesh_term>
	<criteria>Male female ≥ 18 year age diagnosis moderate severe IC ; Bladder pain ≥ 6 month prior baseline ; Urinary frequency ≥ 8 ≤ 30 micturition within 24 hour awake ; Nocturia ≥ 2x/night ; Males females childbearing potential ( surgically sterile postmenopausal ) must abstinent agree use studyaccepted contraceptive regimen throughout study : Female patient child bear age must negative urine pregnancy test screening ; Must provide sign informed consent . Male female &lt; 18 year age ; Initiation new IC medication ≤ 30 day prior baseline ; Treatment Elmiron ≤ 120 day prior baseline ; Treatment bladder hydrodistention ≤ 6 month prior baseline ; Treatment intravesical therapy ≤ 60 day prior baseline ; History previous procedure ( ) ( e.g. , augmentation cytoplasty , cystectomy cystolysis ) affect bladder function ; Active genital herpes vaginitis ≤ 90 day prior baseline ; Urinary tract prostatic infection ≤ 90 day prior baseline ; History urethral diverticulum ; History bladder ureteral calculus ; History cyclophosphamide chemical cystitis , urinary tuberculosis radiation cystitis ; History bladder tumor ; History uterine , cervical , vaginal , prostatic urethral cancer ≤ 5 year prior baseline ; Patient currently pregnant , lactate likely become pregnant study ; Participated another clinical study investigational drug device ≤ 30 day prior baseline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Interstitial Cystitis</keyword>
	<keyword>urgency</keyword>
	<keyword>frequency</keyword>
	<keyword>MN-001</keyword>
	<keyword>Global Response Assessment</keyword>
	<keyword>bladder pain/urgency</keyword>
	<keyword>O'Leary Sant IC Symptom Problem Index</keyword>
</DOC>